Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Expands By 112.5%

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 15th total of 3,200 shares. Based on an average trading volume of 16,400 shares, the short-interest ratio is presently 0.4 days.

Adlai Nortye Price Performance

Shares of Adlai Nortye stock traded up $0.03 during trading on Tuesday, reaching $2.01. 5,735 shares of the company's stock were exchanged, compared to its average volume of 24,667. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48. The firm's 50-day moving average price is $2.40 and its 200 day moving average price is $2.58.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.